Identifying new medication options is critical for curbing the health burdens of cigarette
smoking. Currently approved smoking cessation medications act on nicotinic receptors, and
additional work is needed to identify medications with alternate pharmacological targets.
Based on evidence that the serotonin system plays a role in nicotine consumption and relapse,
this study will examine whether a selective serotonin medication alters smoking-related
behaviors and responses to cigarette smoking under controlled conditions, informing its
potential utility for smoking cessation.